Pluto Biosciences, a Denver, Colorado-based cutting-edge life sciences Software-as-a-Service (SaaS) platform, announced that it closed a $3.7 million seed funding round led by Silverton Partners in Austin, TX.
The funding will use to further build out the product and go-to-market teams, and develop advanced product features.
This investment will fuel the expansion of Pluto's innovative platform, which gives scientific teams both a unified home for managing their biological data, and an industry-first, interactive canvas for analyzing and visualizing complex biological data sets using no-code computational biology pipelines.
"Pluto is breaking down the obstacles that have traditionally prevented the widespread use of computational biology, including the need for compute infrastructure and black box "pipelines," and empowering scientists to play an active role in their scientific discoveries,” says Rani Powers, PhD, CEO and Founder of Pluto. Dr. Powers is confident that the investment will accelerate Pluto's growth and enable the company to reach even more organizations in the life sciences industry. “With Silverton Partners' support, we will be able to increase sales velocity with the ultimate goal of transforming the way life sciences research is conducted.”
Company: Pluto Biosciences, Inc.
Raised: $3.7M
Round: Seed Round
Funding Month: May 2023
Lead Investors: Silverton Partners
Additional Investors:
Company Website: https://pluto.bio/
Software Category: Life Sciences SaaS Platform
About the Company: Founded in 2020, Pluto is a collaborative life sciences platform re-envisioning the scientific research process from the ground up. Built for life science organizations of all sizes, Pluto delivers a visually elegant platform that allows for easy management of lab projects, secure data sharing with collaborators, as well as the execution of computational biology analyses and visualization. The platform can be used to analyze data from popular next-generation sequencing-based assays such as RNA-seq, ChIP-seq, CUT&RUN, and CRISPR screens and data from other workhorse assays for pharma and biotech, including metabolomics, proteomics, biochemical assays, and animal behavioral studies. The Pluto platform also integrates with sequencing services, electronic lab notebooks, project management platforms, and other collaboration tools.
Source: https://pluto.bio/blog/pluto-raise-to-revolutionize-biological-data-interpretation